We have some brilliant chemists and scientists on our side.
They have been able to design a small molecule that binds with PCSK9, something big pharma was unable to do. They then created more powerful version of their original breakthrough compound and were then able to modify those compounds to remove unwanted side effects. In the process they created extensive Intellectual Property that informed a series of Patent Applications
By submitting this detailed paper for publication, Nyrada implies that competitors will not be able to use the information, because the IP is locked up. The paper will garner scientific credibility for our PCSK9 inhibitor, and enable potential partners to evaluate to potential worth of our anti-cholesterol program.
This work will certainly be on the radar of many large companies. Will they wait for human trials? I doubt it.
NYR Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)